Trials / Completed
CompletedNCT02396966
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
A Prospective, Non-interventional, Observational, Multi-centre Study to Document QoL of Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 152 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).
Conditions
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2015-03-24
- Last updated
- 2018-12-21
Locations
18 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT02396966. Inclusion in this directory is not an endorsement.